Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus OXILAN 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus OXILAN 350.
HYPAQUE-M,90% vs OXILAN-350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Iodinated contrast medium that attenuates X-rays due to its iodine content, enhancing vascular and tissue contrast during imaging. It distributes in extracellular fluid and is freely filtered by glomeruli.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
Intravenous: 0.5–2 mL/kg (350 mg I/mL) for CT imaging; maximum 200 mL total. Intra-arterial: 0.3–1.5 mL/kg per injection; maximum 200 mL per procedure.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 24 hours in severe impairment).
Renal: >95% unchanged; biliary/fecal: <5%
Renal: >90% unchanged drug within 24 hours; Biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent